Clinical Trial Update: BMS-986253 in Myelodysplastic Syndromes [Phase 1, Phase 2]

View source ↗

Summary

The clinical trial update reports a terminated Phase 1/2 study of BMS-986253 in myelodysplastic syndromes with results posted on 2024-06-11.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• BMS-986253 (BMS-986253)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Myelodysplastic Syndromes | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-06-11